Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 9/20 | 0.63 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.63 |
| ▸ | KDM5A | P29375 | 2/20 | 0.63 |
| ▸ | KDM3A | Q9Y4C1 | 2/20 | 0.63 |
| ▸ | KDM4A | O75164 | 2/20 | 0.63 |
| ▸ | KDM5C | P41229 | 2/20 | 0.63 |
| ▸ | KDM5B | Q9UGL1 | 2/20 | 0.63 |
| ▸ | ASPH | Q12797 | 2/20 | 0.63 |
| ▸ | KDM8 | Q8N371 | 2/20 | 0.63 |
| ▸ | KDM6B | O15054 | 1/20 | 0.63 |
| ▸ | TET3 | O43151 | 1/20 | 0.63 |
| ▸ | BBOX1 | O75936 | 1/20 | 0.63 |
| ▸ | MAPT | P10636 | 1/20 | 0.63 |
| ▸ | KDM4D | Q6B0I6 | 1/20 | 0.63 |
| ▸ | TET2 | Q6N021 | 1/20 | 0.63 |
| ▸ | ALKBH5 | Q6P6C2 | 1/20 | 0.63 |
| ▸ | KDM7A | Q6ZMT4 | 1/20 | 0.63 |
| ▸ | TET1 | Q8NFU7 | 1/20 | 0.63 |
| ▸ | EGLN2 | Q96KS0 | 1/20 | 0.63 |
| ▸ | FTO | Q9C0B1 | 1/20 | 0.63 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7513922 | 0.81 | KMO (0.71) | KDM4EALDH1A1KDM5AKDM3AKDM4A | |
| SCHEMBL30800092 | 0.81 | KMO (0.71) | KDM4EALDH1A1KDM5AKDM3AKDM4A | |
| SCHEMBL159513 | 0.80 | ADORA3 (0.47) | KDM4EALDH1A1KDM5AKDM3AKDM4A | |
| SCHEMBL29951101 | 0.77 | KDM4E (0.63) | KDM4EALDH1A1KDM5AKDM3AKDM4A | |
| SCHEMBL29382783 | 0.77 | KDM5C (1.00) | KDM4EALDH1A1KDM5AKDM3AKDM4A | |
| SCHEMBL72377 | 0.77 | KDM5C (1.00) | KDM4EALDH1A1KDM5AKDM3AKDM4A | |
| SCHEMBL65841 | 0.77 | KDM4E (0.63) | KDM4EALDH1A1KDM5AKDM3AKDM4A | |
| SCHEMBL163711 | 0.77 | KDR (0.48) | KDM4EALDH1A1MAPTKDM4CLMNA | |
| Hydrochloric Acid SCHEMBL10778857 | 0.76 | KDM5C (0.96) | KDM4EALDH1A1KDM5AKDM3AKDM4A | |
| SCHEMBL202448 | 0.76 | ALDH1A1 (0.61) | KDM4EALDH1A1KDM5AKDM3AKDM4A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9856210-B2 | Pharmaceutical composition for prevention and treatment of amyotrophic lateral sclerosis | KYOTO UNIVERSITY (JP) | 2018-01-02 | — | — | US | disclosed |
| EP-2611437-B1 | PHARMACEUTICAL COMPOSITION FOR PREVENTION AND TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS | UNIV KYOTO (JP) | 2017-03-29 | — | — | EP | disclosed |
| US-20130225642-A1 | PHARMACEUTICAL COMPOSITION FOR PREVENTION AND TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS | KYOTO UNIVERSITY (JP) | 2013-08-29 | — | — | US | disclosed |
| EP-2611437-A1 | PHARMACEUTICAL COMPOSITION FOR PREVENTION AND TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS | Kyoto University (JP) | 2013-07-10 | — | — | EP | disclosed |
| WO-2012029994-A1 | PHARMACEUTICAL COMPOSITION FOR PREVENTION AND TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS | KYOTO UNIVERSITY (JP) | 2012-03-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130225642-A1 | PHARMACEUTICAL COMPOSITION FOR PREVENTION AND TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS | SMN1; SMN2, SOD1, SOD3 | KDM4E 2214/4885ALDH1A1 1667/4885KDM5A 1920/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.